<SEC-DOCUMENT>0001104659-21-008822.txt : 20210128
<SEC-HEADER>0001104659-21-008822.hdr.sgml : 20210128
<ACCEPTANCE-DATETIME>20210128164756
ACCESSION NUMBER:		0001104659-21-008822
CONFORMED SUBMISSION TYPE:	S-3/A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20210128
DATE AS OF CHANGE:		20210128

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISCELLANEOUS BUSINESS SERVICES [7380]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		S-3/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-252280
		FILM NUMBER:		21565858

	BUSINESS ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631-240-8800

	MAIL ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3/A
<SEQUENCE>1
<FILENAME>tm214491d1_s3a.htm
<DESCRIPTION>S-3/A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"> <B>As filed with the Securities and Exchange
Commission on January 28, 2021<BR>
Registration No. 333-<B>252280</B></B> </P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>AMENDMENT NO. 1</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>TO</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-3 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>UNDER<BR>
THE SECURITIES ACT OF 1933</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>APPLIED
DNA SCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B>(Exact
name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Delaware</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of incorporation
        or organization)</P></TD>
    <TD STYLE="width: 38%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 31%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">59-2262718</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer Identification</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Number)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>50 Health Sciences Drive<BR>
Stony Brook, New York 11790<BR>
(631) 240-8800<BR>
</B>(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>James A. Hayward, Ph.D., Sc.D., Chief
Executive Officer<BR>
Applied DNA Sciences, Inc.<BR>
50 Health Sciences Drive<BR>
Stony Brook, New York 11790<BR>
(631) 240-8800<BR>
</B>(Name, address, including zip code, and telephone number, including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Please send copies of all communications
to:</I><BR>
<B>Merrill M. Kraines, Esq.<BR>
Troutman Pepper Hamilton Sanders LLP<BR>
875 Third Avenue<BR>
New York, New York 10022<BR>
Telephone: 212-808-2711<BR>
Facsimile: 212-658-9982</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Approximate date of commencement of proposed sale to the public:
From time to time after this Registration Statement becomes effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the only securities being registered on this form are being
offered pursuant to dividend or interest reinvestment plans, please check the following box.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If any of the securities being registered on this form are to
be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933, as amended (&#8220;<U>Securities
Act</U>&#8221;), other than securities offered only in connection with dividend or interest reinvestment plans, check the following
box.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is filed to register additional securities for
an offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box and list the Securities Act Registration
Statement number of the earlier effective Registration Statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is a post-effective amendment filed pursuant to
Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act Registration Statement number of
the earlier effective Registration Statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is a Registration Statement pursuant to General
Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to
Rule 462(e) under the Securities Act, check the following box.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is a post-effective amendment to a registration
statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities
pursuant to Rule 413(b) under the Securities Act, check the following box.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions
of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging
growth company&#8221; in rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top; width: 21%"><FONT STYLE="font-size: 10pt">Large Accelerated Filer</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top; width: 51%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top; width: 22%"><FONT STYLE="font-size: 10pt">Accelerated Filer</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top; width: 3%"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Non-Accelerated Filer</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Smaller Reporting Company</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top; width: 21%">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top; width: 51%">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top; width: 22%"><FONT STYLE="font-size: 10pt">Emerging Growth Company</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top; width: 3%"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 7(a)(2)(B) of the Securities Act. <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11pt 0pt 25pt; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The registrant hereby amends this registration statement
on such date or dates as may be necessary to delay its effective date until we shall file a further amendment which specifically
states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act
or until the registration statement becomes effective on such date as the Securities and Exchange Commission, acting pursuant to
said Section 8(a), may determine.</B></P>








<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>CALCULATION
OF REGISTRATION FEE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Title
    of each class of </B><BR>
    <B>securities</B><BR>
    <B>&nbsp;to be registered</B></FONT> </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Amount
    </B><BR>
    <B>to be </B><BR>
    <B>registered (1)</B></FONT> </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Proposed</B><BR>
    <B>maximum</B><BR>
    <B>offering price</B><BR>
    <B>per unit (2)</B></FONT> </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Proposed
    </B><BR>
    <B>maximum</B><BR>
    <B>aggregate</B><BR>
    <B>offering price (2)</B></FONT> </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Amount
    of </B><BR>
    <B>registration fee</B></FONT> </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 39%; background-color: #CCEEFF"> <FONT STYLE="font-size: 10pt">Common stock, par value $0.001 per share
    (3)</FONT> </TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF"> &nbsp; </TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF"> &nbsp; </TD>
    <TD STYLE="width: 10%; background-color: #CCEEFF; text-align: right"> <FONT STYLE="font-size: 10pt">259,000</FONT> </TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF"> &nbsp; </TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF"> &nbsp; </TD>
    <TD STYLE="width: 2%; background-color: #CCEEFF"> <FONT STYLE="font-size: 10pt">&nbsp;$</FONT> </TD>
    <TD STYLE="width: 10%; background-color: #CCEEFF; text-align: right"> <FONT STYLE="font-size: 10pt">9.08&nbsp;</FONT> </TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF"> &nbsp; </TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF"> &nbsp; </TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF"> <FONT STYLE="font-size: 10pt">&nbsp;$</FONT> </TD>
    <TD STYLE="width: 13%; background-color: #CCEEFF; text-align: right"> <FONT STYLE="font-size: 10pt">2,350,425&nbsp;</FONT> </TD>
    <TD STYLE="white-space: nowrap; width: 2%; background-color: #CCEEFF"> &nbsp; </TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF"> &nbsp; </TD>
    <TD STYLE="width: 2%; background-color: #CCEEFF"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="width: 11%; background-color: #CCEEFF; text-align: right"> 256.86 </TD>
    <TD STYLE="white-space: nowrap; width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: white"> &nbsp; </TD>
    <TD STYLE="background-color: white"> &nbsp; </TD>
    <TD STYLE="background-color: white"> &nbsp; </TD>
    <TD STYLE="background-color: white; text-align: right"> &nbsp; </TD>
    <TD STYLE="background-color: white"> &nbsp; </TD>
    <TD STYLE="background-color: white"> &nbsp; </TD>
    <TD STYLE="background-color: white"> &nbsp; </TD>
    <TD STYLE="background-color: white; text-align: right"> &nbsp; </TD>
    <TD STYLE="background-color: white"> &nbsp; </TD>
    <TD STYLE="background-color: white"> &nbsp; </TD>
    <TD STYLE="background-color: white"> &nbsp; </TD>
    <TD STYLE="background-color: white; text-align: right"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; background-color: white"> &nbsp; </TD>
    <TD STYLE="background-color: white"> &nbsp; </TD>
    <TD STYLE="background-color: white"> &nbsp; </TD>
    <TD STYLE="background-color: white; text-align: right"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: #CCEEFF; padding-bottom: 2.5pt"> <FONT STYLE="font-size: 10pt">Total</FONT> </TD>
    <TD STYLE="background-color: #CCEEFF; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 2.25pt double; background-color: #CCEEFF"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 2.25pt double; background-color: #CCEEFF; text-align: right"> <FONT STYLE="font-size: 10pt">259,000</FONT> </TD>
    <TD STYLE="background-color: #CCEEFF; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="background-color: #CCEEFF; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="background-color: #CCEEFF; padding-bottom: 2.5pt"> <FONT STYLE="font-size: 10pt">&nbsp;$</FONT> </TD>
    <TD STYLE="background-color: #CCEEFF; padding-bottom: 2.5pt; text-align: right"> <FONT STYLE="font-size: 10pt">9.08&nbsp;</FONT> </TD>
    <TD STYLE="background-color: #CCEEFF; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="background-color: #CCEEFF; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="background-color: #CCEEFF; padding-bottom: 2.5pt"> <FONT STYLE="font-size: 10pt">&nbsp;$</FONT> </TD>
    <TD STYLE="background-color: #CCEEFF; padding-bottom: 2.5pt; text-align: right"> <FONT STYLE="font-size: 10pt">2,350,425&nbsp;</FONT> </TD>
    <TD STYLE="white-space: nowrap; background-color: #CCEEFF; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="background-color: #CCEEFF"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 2.25pt double; background-color: #CCEEFF"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="border-bottom: black 2.25pt double; background-color: #CCEEFF; text-align: right"> 256.86 (4) </TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) Pursuant to Rule 416 under the Securities Act of 1933, as
amended (the &#8220;Securities Act&#8221;), the securities being registered hereunder also include such indeterminate number of
additional shares of common stock as may from time to time be issued after the date hereof as a result of stock splits, stock dividends,
recapitalizations or similar transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) Estimated solely for the purpose of calculating the registration
fee in accordance with Rule 457(c) of the Securities Act, based on the average of the high and low prices of the common stock of
the registrant as reported on The Nasdaq Capital Market on January 14, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3) Represents shares of our common stock offered by the Selling
Stockholders issuable upon the exercise of warrants to purchase common stock issued to the Selling Stockholders in a private placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(4) Previously paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="color: Red; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information contained in
this prospectus is not complete and may be changed. The selling stockholders named in this prospectus may not sell these securities
until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer
to sell these securities and we are not soliciting offers to buy these securities in any jurisdiction where such offer or sale
is not permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: red">&nbsp;</P>

<P STYLE="color: Red; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> SUBJECT TO COMPLETION, DATED
JANUARY 28, 2021 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm214491d1_s3img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APPLIED DNA SCIENCES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>259,000 SHARES OF COMMON STOCK ISSUED
PURSUANT TO THE EXERCISE OF WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus relates to the resale by
the selling stockholders named herein, including their transferees, pledgees or donees, or their respective successors, of up
to 259,000 shares (the &#8220;Shares&#8221;) of Applied DNA Sciences, Inc. (the &#8220;Company&#8221;)&#8217;s common stock, $.001
par value, issuable upon the exercise of warrants (the &#8220;Warrants&#8221;) to purchase 259,000 shares of common stock. Dillon
Hill Capital, LLC and its affiliate, Dillon Hill Investment Company LLC, are collectively, the &#8220;Selling Stockholders&#8221;.
For information about the Selling Stockholders, see &#8220;Selling Stockholders&#8221; on page 21.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our common stock offered by the Selling
Stockholders will be issued pursuant to the exercise of Warrants in accordance with their terms. The Warrants were issued in connection
with certain Warrant Exercise Agreements entered into by us with each of the Selling Stockholders. See &#8220;Private Placement
of Warrants.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are not selling any securities under
this prospectus and will not receive any of the proceeds from the sale of common stock by the Selling Stockholders, except for
funds received from the exercise of Warrants held by the Selling Stockholders, if and when exercised for cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Selling Stockholders may sell shares of common stock (the
 &ldquo;Securities&rdquo;) from time to time in the principal markets on which the common stock is quoted at the prevailing market
price, at prices related to prevailing market prices or in negotiated transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Selling Stockholders may sell shares
to or through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, concessions or commissions
from the Selling Stockholders, the purchasers of the shares, or both.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are registering the offer and sale of
the Securities pursuant to certain registration rights granted to the Selling Stockholders. The timing and amount of any sale of
common stock is within the sole discretion of each Selling Stockholder. We do not know when or in what amount the Selling Stockholders
may offer the Securities for sale. We will pay the expenses of registering these Securities, including legal and accounting fees.
All selling and other expenses incurred by the Selling Stockholders will be borne by the Selling Stockholders. See &#8220;Plan
of Distribution.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our common stock is traded on The Nasdaq
Capital Market under the symbol &#8220;APDN&#8221;. On January 27, 2021, the closing sales price for our common stock on The Nasdaq
Capital Market was $10.87 per share. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>The purchase of the common stock offered
through this prospectus involves a high degree of risk. You should consider carefully the risk factors beginning on page 15
of this prospectus before purchasing any of the securities offered by this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>We may amend or supplement this prospectus
from time to time by filing amendments or supplements as required. You should read the entire prospectus and any amendments or
supplements carefully before you make your investment decision.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Neither the Securities and Exchange Commission
(&#8220;SEC&#8221;) nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy
or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>The date of this prospectus is January
&nbsp;&nbsp;&nbsp;, 2021.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>TABLE OF CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: left"><A HREF="#a_001">ABOUT THIS PROSPECTUS</A></TD>
    <TD STYLE="width: 10%; text-align: right"><A HREF="#a_001">4</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_002">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_002">5</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_003">PROSPECTUS SUMMARY</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_003">7</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_004">SUMMARY OF RISKS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_004">12</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_005">CORPORATE INFORMATION</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_005">13</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_006">THE OFFERING</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_006">14</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_007">RISK FACTORS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_007">15</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#c_001">USE OF PROCEEDS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#c_001">18</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#c_002">DIVIDEND POLICY</A></TD>
    <TD STYLE="text-align: right"><A HREF="#c_002">18</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#c_003">PRIVATE PLACEMENT OF WARRANTS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#c_003">19</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#c_004">SELLING STOCKHOLDERS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#c_004">21</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#c_005">PLAN OF DISTRIBUTION</A></TD>
    <TD STYLE="text-align: right"><A HREF="#c_005">23</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_008">LEGAL MATTERS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_008">26</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_009">EXPERTS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_009">26</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_010">WHERE YOU CAN FIND MORE INFORMATION</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_010">26</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_011">INFORMATION INCORPORATED BY REFERENCE</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_011">26</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_012">INFORMATION NOT REQUIRED IN THE PROSPECTUS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_012">29</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_013">INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_013">29</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_014">EXHIBIT INDEX</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_014">34</A></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_001"></A>ABOUT THIS
PROSPECTUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information contained in this prospectus
is not complete and may be changed. You should rely only on the information provided in or incorporated by reference in this prospectus,
in any prospectus supplement or in a related free writing prospectus, or documents to which we otherwise refer you. We have not
authorized anyone else to provide you with different information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have not authorized any dealer, agent
or other person to give any information or to make any representation other than those contained or incorporated by reference in
this prospectus and any accompanying prospectus supplement or any related free writing prospectus. You must not rely upon any information
or representation not contained or incorporated by reference in this prospectus or an accompanying prospectus supplement or any
related free writing prospectus. This prospectus and any accompanying prospectus supplement and any related free writing prospectus,
if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities
to which they relate, nor do this prospectus and any accompanying prospectus supplement and any related free writing prospectus,
if any, constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom
it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in
this prospectus and any accompanying prospectus supplement and any related free writing prospectus, if any, is accurate on any
date subsequent to the date set forth on the front of such document or that any information we have incorporated by reference is
correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus and any accompanying
prospectus supplement and any related free writing prospectus is delivered or securities are sold on a later date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have not done anything that would permit
this offering or possession or distribution of this prospectus or any free writing prospectus in any jurisdiction where action
for that purpose is required, other than in the United States. You are required to inform yourself about and to observe any restrictions
relating as to this offering and the distribution of this prospectus and any such free writing prospectus outside the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We further note that the representations,
warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference
in this prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose
of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant
to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such
representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In this prospectus &#8220;Applied DNA,&#8221;
the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Applied DNA Sciences, Inc. and its
subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_002"></A>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus <FONT STYLE="background-color: white">and
any applicable prospectus supplement or free writing prospectus</FONT> and the documents incorporated by reference herein and therein
contain &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended (the
 &#8220;Securities Act&#8221;) and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;),
that are intended to qualify for the &#8220;safe harbor&#8221; created by those sections. In addition, we may make forward-looking
statements in other documents filed with or furnished to the SEC, and our management and other representatives may make forward-looking
statements orally or in writing to analysts, investors, representatives of the media and others. <FONT STYLE="background-color: white">These
statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties
and other factors which may cause our actual results, performance or achievements to be materially different from any future results,
performances or achievements expressed or implied by the forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Forward-looking statements can generally
be identified by the fact that they do not relate strictly to historical or current facts and include, but are not limited to,
statements using terminology such as &#8220;can&#8221;, &#8220;may&#8221;, &#8220;could&#8221;, &#8220;should&#8221;, &#8220;assume&#8221;,
 &#8220;forecasts&#8221;, &#8220;believe&#8221;, &#8220;designed to&#8221;, &#8220;will&#8221;, &#8220;expect&#8221;, &#8220;plan&#8221;,
 &#8220;anticipate&#8221;, &#8220;estimate&#8221;, &#8220;potential&#8221;, &#8220;position&#8221;, &#8220;predicts&#8221;, &#8220;strategy&#8221;,
 &#8220;guidance&#8221;, &#8220;intend&#8221;, &#8220;seek&#8221;, &#8220;budget&#8221;, &#8220;project&#8221; or &#8220;continue&#8221;,
or the negative thereof or other comparable terminology regarding beliefs, plans, expectations or intentions regarding the future,
including risks relating to the continuing outbreak of the coronavirus (COVID-19). You should read statements that contain these
words carefully because they:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">discuss our future expectations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">contain projections of our future results of operations or of our financial condition; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">state other &#8220;forward-looking&#8221; information.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe it is important to communicate
our expectations. However, forward-looking statements are based on our current expectations, assumptions, estimates and projections
about our business and our industry and are subject to known and unknown risks, uncertainties and other factors. Accordingly, our
actual results and the timing of certain events may differ materially from those expressed or implied in such forward-looking statements
due to a variety of factors and risks, including, but not limited to, those set forth under &#8220;Risk Factors&#8221; and &#8220;Prospectus
Summary &#8211; Our Company&#8221; set forth in this prospectus and those set forth from time to time in our other filings with
the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our forward-looking statements address,
among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our expectations of future revenues, expenditures, capital or other funding requirements;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the adequacy of our cash and working capital to fund present and planned operations and growth;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our business strategy and the timing of our expansion plans;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our expectations concerning product candidates for our technologies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our expectations concerning existing or potential development and license agreements for third-party collaborations and joint ventures;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our expectations of when different phases of clinical activity may commence and conclude;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the effect of governmental regulations generally;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our expectations of when regulatory submissions may be filed or when regulatory clearances or approvals may be received; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our expectations of when or if we will become profitable.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any or all of our forward-looking statements
may turn out to be wrong. They may be affected by inaccurate assumptions that we might make or by known or unknown risks and uncertainties.
Actual outcomes and results may differ materially from what is expressed or implied in our forward-looking statements. Among the
factors that could affect future results are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the inherent uncertainties of product development based on our new and as yet not fully proven technologies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the risks and uncertainties regarding the actual effect on humans of seemingly safe and efficacious formulations and treatments when tested clinically;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the inherent uncertainties associated with clinical trials of product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the inherent uncertainties associated with the process of obtaining regulatory clearance or approval to market product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the inherent uncertainties associated with commercialization of products that have received regulatory clearance or approval;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">economic and industry conditions generally and in our specific markets;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the volatility of, and decline in, our stock price; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our current lack of financing for operations and our ability to obtain the necessary financing to fund our operations and effect our strategic development plan.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All forward-looking statements and risk
factors included in this prospectus and the documents incorporated herein by reference are made as of the date hereof, or in the
case of documents incorporated by reference, the original date of any such documents, based on information available to us as of
such date, and we assume no obligations to update any forward-looking statement or risk factor, unless we are required to do so
by law. If we do update one or more forward-looking statements, no inference should be drawn that we will make updates with respect
to other forward-looking statements or that we will make any further updates to those forward-looking statements at any future
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any of the assumptions underlying the forward-looking
statements contained in this prospectus and the documents incorporated herein by reference could prove inaccurate and, therefore,
we cannot assure you that the results contemplated in any of such forward-looking statements will be realized. Based on the significant
uncertainties inherent in these forward-looking statements, the inclusion of any such statement should not be regarded as a representation
or as a guarantee by us that our objectives or plans will be achieved, and we caution you against relying on any of the forward-looking
statements contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_003"></A>PROSPECTUS
SUMMARY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> This summary highlights certain information
about us, this offering and information appearing elsewhere in this prospectus and in the documents we incorporate by reference
in this prospectus. This summary is not complete and does not contain all of the information that you should consider before investing
in our securities. After you carefully read this summary, to fully understand our company and this offering and its consequences
to you, you should read this entire prospectus and any related free writing prospectus authorized by us, including the information
referred to under the heading &#8220;Risk Factors&#8221; in this prospectus beginning on page 15, and any related free writing
prospectus, as well as the other documents that we incorporate by reference into this prospectus, including our financial statements
and the notes to those financial statements, which are incorporated herein by reference from our <A HREF="http://www.sec.gov/Archives/edgar/data/744452/000110465920136828/tm2037742d1_10k.htm" STYLE="-sec-extract: exhibit">Annual
Report on Form 10-K for the year ended September 30, 2020, filed on December 17, 2020, as amended by Amendment No. 1 filed on
January 27, 2021</A>. Please read &#8220;Where You Can Find More Information&#8221; on page 26 of this prospectus. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Overview</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our proprietary PCR-based DNA LinearDNA<SUP>TM
</SUP>manufacturing platform produces large quantities of DNA for use in nucleic acid-based in vitro medical diagnostics and preclinical
nucleic acid-based drug development and manufacturing markets (&#8220;Biotherapeutic Contract Research and Manufacturing&#8221;)
and for supply chain security, anti-counterfeiting and anti-theft technology purposes (&#8220;Non-Biologic Tagging&#8221;). In
response to the SARS-CoV-2 (&#8220;COVID-19&#8221;) pandemic, the Company developed a PCR-based molecular diagnostic test for COVID-19,
which was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in May 2020. The
Company currently manufactures and sells its EUA authorized COVID-19 molecular diagnostic test kit under the Linea<SUP>TM </SUP>COVID-19
Assay Kit trademark (&#8220;COVID-19 Diagnostic Testing&#8221;). In addition, and in further response to the COVID-19 pandemic,
the Company developed and is currently offering non-diagnostic COVID-19 pooled surveillance testing to detect instances of COVID-19
in defined populations. The Company&#8217;s COVID-19 pooled surveillance testing services are currently offered under the safeCircle<SUP>TM</SUP>
trademark (&#8220;COVID-19 Surveillance Testing&#8221;). The Company is also developing an invasive circulating tumor cell capture
and identification technology (&#8220;iCTC Technology&#8221;) which uses a patented functional assay to capture live invasive circulating
tumor cell and associated lymphocytes that can be identified and expanded for further analysis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Applied DNA&#8217;s LinearDNA<SUP>TM</SUP>
PCR platform is capable of producing large scale DNA, which we believe offers many benefits over the limitations of other large
scale DNA manufacturing systems, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Speed &#8211; Production of DNA via the LinearDNA<SUP>TM</SUP> platform can be measured in terms of hours, not days and weeks like other large scale DNA manufacturing platforms.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Scale &#8211; The LinearDNA<SUP>TM</SUP> platform is flexible and can be adapted to encompass large quantity production.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Purity &#8211; DNA produced via PCR is pure, resulting in only large quantities of the target DNA sequence. Unwanted DNA sequences such as bacterially-derived DNA are not present.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Customization &#8211; DNA produced via PCR can be easily chemically modified to suit specific customer applications.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Biotherapeutic Contract Research and Manufacturing</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our patented continuous flow PCR systems
and other proprietary PCR-based production technology and post-processing systems that comprise the LinearDNA<SUP>TM</SUP> platform
allows for the large-scale production of specific DNA sequences. The LinearDNA<SUP>TM</SUP> platform is currently being used for
customers to manufacture DNA as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development
in the fields of adoptive cell therapies (CART and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered
regularly interspaced short palindromic repeats (CRISPR) based therapies and gene therapies. We believe our LinearDNA<SUP>TM</SUP>
platform confers a distinct competitive advantage in cost, cleanliness, and time-to-market as compared to other DNA manufacturing
systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We provide preclinical contract research
and manufacturing services for the nucleic acid-based therapeutic markets. We work with biotech and pharmaceutical companies to
convert plasmid-based and/or viral transduction-based preclinical biotherapeutics into PCR-produced linear DNA-based forms that
can be produced on our LinearDNA<SUP>TM</SUP> platform. In addition, we provide contract research services to RNA based drug and
biologic customers for preclinical studies. These services include the design, development and manufacture of PCR-produced DNA
templates for RNA. In addition, we also use our LinearDNA<SUP>TM</SUP> platform to produce very large gram-scale quantities of
DNA for the in vitro diagnostic market where our DNA is used for both commercially available diagnostics and diagnostics under
development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also seek to develop, acquire, and commercialize,
ourselves or with partners, a diverse portfolio of nucleic acid-based therapeutics based on PCR-produced linear DNA to improve
existing nucleic acid-based therapeutics or to create new nucleic acid-based therapeutics that address unmet medical needs. We
are currently directly engaged in preclinical drug candidate development activities focusing on therapeutically-relevant DNA constructs
manufactured via our LinearDNA<SUP>TM</SUP> platform in the fields of DNA-based anti-viral and anti-cancer vaccines, CAR-T cell
immunotherapy and the manufacture of rAAV vectors for gene therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are also engaged in preclinical and animal
drug candidate development activities focusing on therapeutically relevant DNA constructs manufactured via our PCR-based production
platform. We seek to develop, acquire and commercialize, alone or with partners, a diverse portfolio of nucleic acid-based therapeutics
based on PCR-produced linear DNA which we believe will improve existing nucleic acid-based therapeutics or create new nucleic acid-based
therapeutics that address unmet medical needs. To this end, we are currently working with our development partners Takis S.R.L.
and Evvivax S.R.L. (&#8220;Takis/Evvivax&#8221;) to develop an amplicon-based linear DNA vaccine for COVID-19 that would be manufactured
on our LinearDNA<SUP>TM</SUP> platform. Together with our development partners, our amplicon-based linear COVID-19 vaccine candidate
has shown efficacy in preclinical cell and small animal studies. In September 2020, we entered into an Animal Clinical Trial Agreement
with Takis/Evvivax and with Veterinary Oncology Services, PLLC, an affiliate of Guardian Veterinary Specialists (&#8220;GVS&#8221;),
a multi-specialty veterinary hospital. In November 2020, we, together with Takis/Evvivax and GVS, announced receipt of approvals
from the New York State Department of Agriculture and Markets and the U.S. Department of Agriculture (&#8220;USDA&#8221;) on an
advanced clinical strategy to conduct a veterinary trial of a vaccine candidate. Our jointly-developed amplicon-based DNA vaccine
for COVID-19 is expected to start veterinary clinical trials in domestic feline cats by early 2021, with the end goal of applying
for a USDA Animal and Plant Health Inspection Service conditional license to enable commercial veterinary sales for domestic felines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>COVID-19 Diagnostic Testing</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On May 13, 2020 we received an EUA from
the FDA for the clinical use of the Linea<SUP>TM</SUP> COVID-19 Assay Kit for the qualitative detection of nucleic acid from SARS-CoV-2
in respiratory specimens including anterior nasal swabs, self-collected at a healthcare location or collected by a healthcare worker,
and nasopharyngeal and oropharyngeal swabs, mid-turbinate nasal swabs, nasopharyngeal washes/aspirates or nasal aspirates, and
bronchoalveolar lavage specimens collected by a healthcare worker from individuals who are suspected of COVID-19 by their healthcare
provider. Under the EUA, testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988,
42 U.S.C. &sect;263a (&#8220;CLIA&#8221;), that meet requirements to perform high complexity tests, which certification we have
applied for but have not yet obtained. As a result, we currently can sell the tests to CLIA laboratories that satisfy such requirements
to perform high complexity tests, but we cannot currently perform the test for the purpose of providing patient specific results.
Subsequently, during July and November 2020, we were granted EUA amendments that expand the installed base of PCR equipment platforms
on which our Linea&#8482; COVID-19 Assay Kit can be processed and significantly increased the daily testing capacity of the Linea&#8482;
COVID-19 Assay Kit through the use of automation. The scope of the EUA, as amended, is expressly limited to use consistent with
the Instructions for Use by authorized laboratories, certified under CLIA to perform high complexity tests. The EUA will be effective
until the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics for detection
and/or diagnosis of COVID-19 is terminated or until the EUA&#8217;s prior termination or revocation. Our Linea&#8482; COVID-19
Assay Kit has not been FDA cleared or approved, and the EUA&#8217;s limited authorization is only for the detection of nucleic
acid from SARS-CoV-2, not for any other viruses or pathogens. We currently manufacture the Linea<SUP>TM</SUP> COVID-19 Assay Kit
at our facilities in Stony Brook, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 29, 2020 we announced that
we had entered into a Master Services Agreement with Stony Brook University Hospital to supply the Linea<SUP>TM</SUP> COVID-19
Assay Kit and related automation systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>COVID-19 Surveillance Testing</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Starting in July 2020, the Company under
its wholly-owned subsidiary, Applied DNA Clinical Labs LLC (&#8220;ADCL&#8221;), began offering COVID-19 pooled surveillance testing
to customers as a Testing-as-a-Service (TaaS) offering branded under the safeCircle<SUP>TM</SUP> trademark. Unlike diagnostic testing,
which looks for the occurrence of COVID-19 at the individual level, safeCircle<SUP>TM</SUP> surveillance testing looks for infections
within a defined population or community and can be used for making health management decisions at the population level. safeCircle<SUP>TM</SUP>
surveillance testing uses high-sensitivity pooled COVID-19 testing utilizing the Linea&#8482; COVID-19 Assay Kit. Under the safeCircle<SUP>TM</SUP>
surveillance testing service, pooled test results are returned to the sponsoring organization in the aggregate only, not directly
to the participating individuals, and may be performed without CLIA certification. Once potentially infected portions of a defined
population are identified by the safeCircle<SUP>TM</SUP> surveillance testing service, the individuals comprising the potentially
infected portions of the defined population are referred to follow on diagnostic testing at a clinical lab to obtain individual
results. ADCL is offering its safeCircle<SUP>TM</SUP> surveillance testing in compliance with current CDC, FDA, CMS and New York
State Department of Health recommendations. The use of pooled sampling procedures for the safeCircle<SUP>TM</SUP> surveillance
testing service has been internally validated by ADCL in compliance with current CDC guidance. The use of pooled sampling procedures
is not included in the Linea<SUP>TM</SUP> COVID-19 Assay Kit EUA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We seek to commercialize the safeCircle<SUP>TM</SUP>
surveillance testing TaaS offering with institutional clients such as schools, colleges and businesses. We currently provide safeCircle<SUP>TM</SUP>
surveillance testing to several private schools, New York State-based small enterprises and college athletic programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Clinical Testing Laboratory</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under our ADCL subsidiary, we have applied
to the New York State Department of Health for all necessary licensing to operate a New York State clinical diagnostics laboratory.
These applications are currently pending. Until this licensing is obtained, we will be unable to operate a clinical diagnostic
laboratory and cannot provide individual patient testing results. The New York State Department of Health performed its initial
inspection of our clinical laboratory and identified deficiencies in the clinical standard of practice. These deficiencies need
to be rectified before we can submit a request for re-inspection. We are working to rectify these deficiencies now. Through ADCL,
we seek to further commercialize our EUA authorized Linea<SUP>TM</SUP> COVID-19 Assay Kit and our iCTC Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>iCTC Technology</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We seek to further develop, manufacture
and commercialize our Vita-Assay<SUP>TM</SUP> iCTC Technology acquired from Vitatex, Inc. in August 2019. Our iCTC Technology uses
a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes that can be identified and
expanded for further analysis, including genetic sequencing. We believe our iCTC Technology can be used as an early cancer diagnostic
tool, to facilitate cancer disease progression monitoring, to assess metastatic tumor risk and to discover epitopes to serve as
targets for nucleic-acid based immunotherapies. Our iCTC Technology has been used and is currently being used in a human cancer
drug candidate clinical trial to monitor cancer disease progression in the trial subjects as a Research Use Only diagnostic assay.
We believe our iCTC Technology has several advantages over existing in vitro circulating tumor cell diagnostic technologies that
do not capture live iCTC cells. The Company seeks to further develop and commercialize this technology and to potentially integrate
aspects of the iCTC Technology with the LinearDNA<SUP>TM</SUP> platform for cancer research and nucleic-acid based drug development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Non-Biologic Tagging and Security Products and Services</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our supply chain security business
allows our customers to use non-biologic DNA (molecular) tags manufactured on our LinearDNA<SUP>TM</SUP> platform to mark
objects in a unique manner and then identify these objects by detecting the absence or presence of the molecular tag. We
believe our molecular tags are not economically feasible nor practical to replicate, and that our disruptive tracking
platform offers broad commercial relevance across many industry verticals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The underlying strategy in our tagging business
is to become an authenticity and traceability platform provider for large complex supply chains, particularly in process industries
in which contracts for our products and services are typically larger and recurring over longer duration as compared to our historic
norms, where the benefits to customers and consumers are more significant, and where our forensic security and traceability offer
a unique and protected value. Using our tagging products and technology, manufacturers, brands, and other stakeholders can ensure
authenticity and protect against diversion throughout a product&#8217;s journey from manufacturer to use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">SigNature&reg; Molecular Tags, SigNature&reg;
T Molecular Tags, fiberTyping&reg;, SigNify&reg; Beacon&reg; and CertainT&reg; comprise our principal Non-Biologic tagging and
security technology platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Signature Molecular Tags</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">SigNature&reg; molecular tags manufactured
via our LinearDNA<SUP>TM</SUP> platform form the core of our supply chain security technology platform. They provide forensic power
and protection for a wide array of applications. Highly secure, robust and durable, SigNature&reg; molecular tags are an ingredient
that can be used to fortify brand protection efforts; strengthen supply chain security; and mark, track and convict criminals.
Through our SigNature&reg; molecular tags, custom DNA sequences can be embedded into a wide range of host carriers including natural
and synthetic materials such as cotton, leather, cannabis, ink, varnish, thread, metal coatings, and pharmaceuticals and nutraceuticals.
SigNature&reg; molecular tag formulations are made to be resistant to challenging environments such as heat, cold, vibration, abrasion,
organic solvents, chemicals, UV radiation and other extreme environmental conditions, and can be identified for numerous years
after being embedded directly into or on an item. The sequence of each individual molecular tag is recorded and stored in a secure
database so that we can later detect it to obtain definitive proof of the presence or absence of a specific molecular tag using
a simple in-field test, or in our laboratories. Our in-lab forensic testing capability delivers Certificate of DNA Authentication
(&#8220;CODA&#8221;) or an expert witness report, with expert witness services for some cases. Because DNA can be amplified with
high fidelity, only minute quantities of our molecular tags extracted from our customers&#8217; goods are necessary for successful
analysis and authentication. As a result, SigNature&reg; molecular tags can fold seamlessly into production and logistics workflows
at extremely low concentrations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our SigNature&reg; molecular tags can be
uniquely designed for specific industries. For example, our SigNature&reg; T molecular tags, designed for textiles and apparel
industry, are specially engineered to adhere tenaciously to textile substrates, which make them resistant to standard textile production
conditions. The result is an enduring forensic level molecular tag that remains present from the fiber stage through to the finished
product. Overall SigNature&reg; molecular tags now exist on hundreds of millions of commodity goods ranging from consumer product
packaging to microcircuits to cotton and synthetic fibers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>SigNify&reg;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">SigNify&reg; IF portable DNA readers and
SigNify&reg; consumable reagent test kits provide definitive real-time authentication of molecular tags in the field, providing
a front-line solution for supply chain integrity backed with forensic-level molecular tag authentication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>CertainT&reg;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The CertainT&reg; trademark indicates the
use of our tagging, testing and tracking platforms and solutions, enabling manufacturers, brands and trade organizations to convey
proof of their product claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">CertainT&reg; and other customer applications
include the use of a software platform that enables customers to manage the security of company-marked goods from point of marking
to point of authentication or validation to end of life. The base platform is configurable to customer requirements. Basic functions
offered include molecular tag inventory management, program training and communications, a database of marked items information,
associated documents and images, chain of custody and location tracking, sample authentication processing and CODA downloads, and
other administrative functions.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>FDA Alert and Letter Regarding the Linea&#8482; COVID-19
Assay Kit and COVID-19 Mutations</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On December 29, 2020 the Company received
a letter (the &#8220;FDA Information Request&#8221;)&nbsp; from the FDA requesting certain information about the potential impact
of the 69&#8212;70del SARS-CoV-2 (&#8220;COVID-19&#8221;) mutation (the &#8220;69&#8212;70del mutation&#8221;) on the performance
of the Linea&#8482; COVID-19 Assay Kit. The 69&#8212;70del mutation is a mutation in the S-gene of COVID-19 that is found in several
variants of COVID-19, including, but not limited to the so called &#8220;UK Variant,&#8221; whose technical designation is UK COV202012/01
or the B.1.1.7 variant.&nbsp; The B.1.1.7 variant contains many mutations, including the 69&#8212;70del mutation.<FONT STYLE="color: #333333; background-color: white">&nbsp;
</FONT>The B.1.1.7 variant has been associated with an increased risk of transmission.&nbsp; As a result, early identification
of individuals potentially infected with this variant is important because it could reduce further transmission of COVID-19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In response to the FDA Information Request,
the Company performed analysis of the Linea&#8482; COVID-19 Assay Kit&#8217;s performance in the presence of the 69&#8212;70del
mutation. Results showed that sensitivity of one of the Linea&#8482; COVID-19 Assay Kit&#8217;s two targets, specifically the S1
target, was highly diminished in the presence of the 69&#8212;70del mutation. The sensitivity of the Linea&#8482; COVID-19 Assay
Kit&#8217;s other target (S2) was not impacted by the mutation. This results in a detection pattern in the presence of the 69&#8212;70del
mutation where the sensitivity of the Linea&#8482; COVID-19 Assay Kit&#8217;s S1 target is highly reduced as compared to the sensitivity
of the Linea&#8482; COVID-19 Assay Kit&#8217;s S2 target (&#8220;S-gene target dropout&#8221;). While reduced sensitivity with
molecular diagnostics is typically not desirable, with certain multi-target COVID-19 molecular diagnostic tests such as the Linea&#8482;
COVID-19 Assay Kit, reduced sensitivity in regard to one target allows viral variants to be identified while still detecting the
presence of COVID-19 via the assay&#8217;s other target(s). On December 31, 2020, the Company responded to the FDA Information
Request informing the FDA of the Linea&#8482; COVID-19 Assay Kit&#8217;s S-gene target dropout in the presence of the 69&#8212;70del
mutation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 8, 2021, the FDA issued an Alert
to Health Care Providers and Clinical Laboratory Staff (the &#8220;FDA Alert&#8221;) regarding the potential impact of COVID-19
mutations on the accuracy of COVID-19 molecular diagnostic tests. Coincident with the FDA Alert, the FDA also issued a Letter to
Health Care Providers and Clinical Laboratory Staff (the &#8220;FDA Letter&#8221;). The FDA Alert and the FDA Letter advised that
false negatives are a risk with all laboratory tests, including COVID-19 molecular diagnostic tests. The FDA further advised that
false negatives can occur with any COVID-19 molecular diagnostic test if a mutation occurs in the region of the virus that the
test is designed to assess. The FDA explained that the potential for false negatives with COVID-19 molecular diagnostics may be
increased with tests that only assess a single region of the COVID-19 virus as compared to tests that assess more than one region
of the virus. The FDA stated that it believes the overall impact of COVID-19 mutations on testing accuracy will be low.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA Alert and the FDA Letter also stated
that FDA is conducting continuous data analysis to evaluate all currently EUA authorized molecular tests in light of COVID-19 mutations.
Based on the FDA&#8217;s own analysis and input from manufacturers, the FDA Alert and the FDA Letter identified three EUA authorized
molecular diagnostic tests that might be impacted by currently known COVID-19 mutations. The FDA Alert and the FDA Letter stated
that the Linea&#8482; COVID-19 Assay Kit and one other molecular diagnostic test exhibit S-gene target dropout detection patterns
when certain COVID-19 variants are present, including variants with the 69&#8212;70del mutation, which includes the B.1.1.7 variant.&nbsp;
The FDA Letter further stated that this detection pattern may help with the early identification of new COVID-19 variants in patients,
including variants with the 69&#8212;70del mutation, which could help to reduce the further spread of COVID-19. The FDA Letter
further noted that when the S-gene target dropout is observed in patient samples tested with the identified kits such samples should
be considered for further characterization via full genetic sequencing, which would allow for identification of the specific variant
at issue. The FDA letter further concluded that due to the identified kits&#8217; multi-target design, overall test sensitivity
should not be impacted.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Preliminary First Quarter 2021 Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 4, 2021, the Company
announced that it expects revenues for the first fiscal quarter of 2021 ended December 31, 2020, to be in the range of $1.3
million to $1.6 million compared to revenues of $314,000 in the fourth quarter of fiscal 2020. The sequential growth in
quarterly revenues is driven principally by demand for safeCircle&#8482;, the pooled COVID-19 surveillance testing program
offered by the Company&#8217;s subsidiary, ADCL, and from sales of its Linea&#8482; COVID-19 Assay Kit under EUA by the FDA
EUA). These preliminary unaudited results are based on management&#8217;s initial analysis of operations for the first fiscal
quarter of 2021 ended December 31, 2020, and are subject to review and revision. The Company expects to issue full financial
results for the first fiscal quarter of 2021 in mid-February.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_004"></A>SUMMARY
OF RISKS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our business is subject to numerous risks
and uncertainties, discussed in more detail in the section &#8220;Risk Factors.&#8221; These risks include, among others, the following
key risks:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The COVID-19 global pandemic may continue to materially and adversely impact our business, financial condition and results of operations.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Our ability to continue as a going concern.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">We have a history of net losses.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">We have not produced significant revenues. This makes it difficult to evaluate our future prospects and increases the risk that we will not be successful.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Our opportunities in medical devices, pharmaceuticals and biologics will require substantial additional funding. We may not be successful in our efforts to create a pipeline of product candidates or to develop commercially successful products. If we fail to successfully identify, finance and develop product candidates, our commercial opportunities in medical devices, pharmaceuticals and biologics may be limited.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Our Linea<SUP>TM</SUP> COVID-19 Assay Kit is being sold under a FDA EUA which could be revoked or terminated by the FDA at any time and will cease to be effective once the public health emergency justifying its use ends.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Our COVID-19 Surveillance Testing may become obsolete for a variety of reasons, including an end to the current pandemic. The utility will also be diminished if positivity rates reach levels high enough to render surveillance testing ineffective or inefficient.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Our Linea<SUP>TM</SUP> COVID-19 Assay Kits could become obsolete or their utility could be significantly diminished.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Medical device, pharmaceutical and biologic products are highly complex, and if we or our collaborators and customers are unable to provide quality and timely offerings to our respective customers, our business could suffer.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Pharmaceutical and biologic-related revenue will be dependent on our collaborators&#8217; and customers&#8217; demand for our manufacturing services.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The markets for our medical devices, drug and biologic candidates and linear DNA are very competitive, and we may be unable to continue to compete effectively in these industries in the future.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The markets for our supply chain security and product authentication solutions are very competitive, and we may be unable to continue to compete effectively in these industries in the future.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Intellectual property litigation could harm our business, financial condition and results of operations.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Our joint pursuit of a potential vaccine for COVID-19 is at an early stage and may be unable to produce a vaccine that successfully treats the virus in a timely manner, if at all, and compete successfully with vaccines developed by larger companies.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Medical device, pharmaceutical and biologic-related revenue is generally dependent on regulatory authorization, clearance or approval, oversight and compliance.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The regulatory authorization, clearance and approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory authorization, clearance or approval for our product candidates, we will be unable to generate product revenue from the related product candidates and our business may be substantially harmed.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 48px"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">If the FDA were to begin to enforce regulation of Laboratory Developed Tests, we could
    incur substantial costs and delays associated with trying to obtain pre-market clearance or approval and costs associated
    with complying with post-market requirements if clearance or approval is ever obtained.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">If we are unable to obtain laboratory licensure or we fail to comply with laboratory licensing requirements, we would not be able to offer clinical diagnostic testing services.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">If we fail to comply with healthcare laws, we could face substantial penalties and our business, operations and financial conditions could be adversely affected.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">We need to expand our sales, marketing and support organizations to increase market acceptance of our products and services.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">If we are unable to continue to retain the services of Dr. Hayward, we may not be able to continue our operations.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">We may have conflicts of interest with our affiliates and related parties, and in the past we have engaged in transactions and entered into agreements with affiliates that were not negotiated at arms&#8217; length.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to the above key factors, as
well as other variables affecting our operating results and financial condition, past financial performance may not be a reliable
indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. The
statements above and the statements included in &#8220;Risk Factors&#8221; are important factors that could cause actual results
or events to differ materially from those contained in any forward-looking statements made by us or on our behalf. The risks and
uncertainties described above and in &#8220;Risk Factors&#8221; are not the only ones we face. In addition to the factors discussed
elsewhere in this prospectus and our other reports and documents filed with the SEC, risks and uncertainties not presently known
to us or that we may currently deem immaterial also may impair our business, financial condition, operating results and/or stock
price. If any of the risks and uncertainties described above or in &#8220;Risk Factors&#8221; actually occurs, our business, financial
condition, operating results and/or stock price could be harmed. In the foregoing factors and in &#8220;Risk Factors&#8221;, &#8220;volatility
in our share price&#8221;, &#8220;adverse impact on the price (or value) of our shares&#8221;, &#8220;decline in the price of our
common stock&#8221; and similar terms also refer to our warrants and shares to be received upon exercise of our warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_005"></A>CORPORATE
INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a Delaware corporation, which was
initially formed in 1983 under the laws of the State of Florida as Datalink Systems, Inc. In 1998, we reincorporated in the State
of Nevada, and in 2002, we changed our name to our current name, Applied DNA Sciences, Inc. In December 2008, we reincorporated
from Nevada to the State of Delaware. LineaRx, Inc. was incorporated in Delaware on September 11, 2018. ADCL was formed in Delaware
on June 12, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our corporate headquarters are located at
the Long Island High Technology Incubator at Stony Brook University in Stony Brook, New York, where we established laboratories
for the manufacture of molecular tags, product prototyping, molecular tag authentication, bulk DNA production, as well the manufacture
of our Linea&#8482; COVID-19 Assay Kit and the performance of our COVID-19 Surveillance Testing. The address of our corporate headquarters
is 50 Health Sciences Drive, Stony Brook, New York 11790, and our telephone number is (631) 240-8800. We maintain a website at
www.adnas.com where general information about us is available. The information on, or that may be accessed through, our website
is not incorporated by reference into and should not be considered a part of this prospectus.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_006"></A>THE OFFERING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<DIV STYLE="border: Black 1pt solid; padding: 5pt">

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock to be offered:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; text-align: left">259,000<SUP>(1)</SUP></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -204.6pt; padding-left: 204.6pt">Terms of the Offering:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Each Selling Stockholder will determine when and how to sell the Shares offered in this prospectus, as described in &#8220;Plan of Distribution.&#8221;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-indent: -204.6pt; padding-left: 204.6pt; text-align: left">Use of proceeds:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">We will not receive any proceeds from the sale of Shares in this offering. See the sections titled &#8220;Use of Proceeds&#8221; and &#8220;Selling Stockholders&#8221; for additional information.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-indent: -204.6pt; padding-left: 204.6pt; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -204.6pt; padding-left: 204.6pt">Risk factors:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">You should read the section titled &#8220;Risk Factors&#8221; for a discussion of factors to consider carefully, together with all the other information included in this prospectus, before deciding to invest in our common stock.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-indent: -204.6pt; padding-left: 204.6pt; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -204.6pt; padding-left: 204.6pt">The Nasdaq Capital Market symbol:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8220;APDN&#8221;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 204.6pt; text-indent: -204.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15.7pt; text-indent: -15.7pt">(1) Represents shares of common
stock issuable upon exercise of Warrants held by the Selling Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15.7pt; text-indent: -15.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.2pt; text-indent: -2.2pt">The selling stockholders named
in this prospectus may offer and sell up to 259,000 shares of our common stock. Our common stock is currently listed on The Nasdaq
Capital Market under the symbol &#8220;APDN.&#8221; Shares of our common stock that may be offered under this prospectus will
be fully paid and non-assessable. We will not receive any of the proceeds of sales by the selling stockholders of any of the common
stock covered by this prospectus. We will, however, receive the net proceeds from any warrants that are exercised for cash. Throughout
this prospectus, when we refer to the shares of our common stock being registered on behalf of the selling stockholders for offer
and resale, we are referring to the shares of common stock that have been issued to the selling stockholders and the shares of
common stock issuable upon exercise of Warrants issued in the Private Placement described in the section titled &#8220;Private
Placement&#8221;. When we refer to the Selling Stockholders in this prospectus, we are referring to the Selling Stockholders identified
in this prospectus and, as applicable, their permitted transferees or other successors-in-interest that may be identified in a
supplement to this prospectus or, if required, a post-effective amendment to the registration statement of which this prospectus
is a part.&nbsp;</P>

</DIV>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_007"></A>RISK FACTORS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Investment in our securities involves a high degree of risk.
In addition to the risks and investment considerations discussed elsewhere in this prospectus or any document incorporated by reference
herein, the following factors should be carefully considered by anyone purchasing the securities offered by this prospectus. The
risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to
us or that we currently deem immaterial also may impair our business operations. We also update risk factors from time to time
in our periodic reports on Forms 10-K, 10-Q and 8-K which will be incorporated by reference in this prospectus. If any of the following
risks actually occur, our business could be harmed. In such case, the trading price of our common stock could decline and investors
could lose all or a part of their investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">See also the statements contained under
the heading &#8220;Special Note Regarding Forward Looking Statements&#8221; and &#8220;Summary of Risks.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Relating to this Offering:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B><I>If you purchase the common stock, you may experience
immediate dilution as a result of this offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since the price per share of our common
stock being offered may be substantially higher than the net tangible book value per share of our common stock, you may suffer
immediate and substantial dilution in the net tangible book value of the common stock you purchase in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>You may experience future dilution as a result of future
equity offerings.&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In order to raise additional capital, we
may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common
stock that could result in further dilution to investors purchasing our common stock in this offering or result in downward pressure
on the price of our common stock. We may sell shares of our common stock or other securities in any other offering at prices that
are higher or lower than the prices paid by investors in this offering, and investors purchasing shares or other securities in
the future could have rights superior to existing stockholders. Moreover, to the extent that we issue options or warrants to purchase,
or securities convertible into or exchangeable for, shares of our common stock in the future and those options, warrants or other
securities are exercised, converted or exchanged, stockholders may experience further dilution.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The trading price of our common stock has been, and is
likely to continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which
are beyond our control.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our stock price is volatile. During the
period from January 1, 2020 to January 11, 2021, the closing price of our common stock ranged from a high of $15.21 per share to
a low of $2.80 per share. The stock market in general and the market for smaller pharmaceutical and biotechnology companies in
particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies.
On January 13, 2021, we closed a registered direct public offering of 1,810,000 shares of our common stock to certain institutional
investors, which may increase the volatility of our common stock. As a result of this volatility, you may not be able to sell your
common stock at or above the public offering price and you may lose some or all of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Relating to Our Business:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The COVID-19 global pandemic may continue to materially
and adversely impact our business, financial condition and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our business has been and could
continue to be materially and adversely affected by the outbreak of a widespread health epidemic. The present coronavirus (or
COVID-19) pandemic has disrupted our operations and has affected our business, as government authorities impose mandatory
closures, work-from-home orders and social distancing protocols or impose other restrictions that could materially adversely
affect our ability to adequately staff and maintain our operations. Portions of our business are considered
 &#8220;essential&#8221; such as our government and pharmaceutical contracts, as well as our vaccine and diagnostic candidate
development and our COVID-19 Surveillance Testing. However, we have experienced, and may continue to experience in the
future, facility closures related to our &ldquo;nonessential&rdquo; businesses, and pursuant to the government order, the
Company has reduced the scope of its operations and where possible, certain workers are telecommuting from their homes. As a
result of COVID-19 we have experienced a decline in revenues from non-biological tagging and related services. As the
COVID-19 outbreak and responses to it continue to evolve, we may experience further adverse impacts on our operations,
including our ability to secure supplies, and our ability to access capital on favorable terms, or at all, may be impaired.
There may also be long-term effects on our customers in and the economies of affected countries. Although the duration and
ultimate impact of these factors is unknown at this time, the decline in economic conditions due to COVID-19, or another
disease causing similar impacts, may adversely affect our business, financial condition and results of operations and such
impact may be material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>There is substantial doubt relating to our ability to
continue as a going concern.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have recurring net losses, which have
resulted in an accumulated deficit of $269,835,650 as of September 30, 2020. We have incurred a net loss of $13,028,904 for the
fiscal year ended September 30, 2020. At September 30, 2020, we had cash and cash equivalents of $7,786,743. We have concluded
that these factors raise substantial doubt about our ability to continue as a going concern for one year from the issuance of the
financial statements. In addition, the report from our independent registered public accounting firm for the year ended September
30, 2020 includes an explanatory paragraph stating that our significant losses and needs to raise additional funds to meet our
obligations and sustain operations raise substantial doubt about our ability to continue as a going concern. On January 13, 2021,
we closed a registered direct public offering of 1,810,000 shares of our common stock to certain institutional investors at a price
of $8.30 per share resulting in total gross proceeds of approximately $15,000,000 before deducting placement agent fees and other
offering expenses. We will continue to seek to raise additional working capital through public equity, private equity or debt financings.
If we fail to raise additional working capital, or do so on commercially unfavorable terms, it would materially and adversely affect
our business, prospects, financial condition and results of operations, and we may be unable to continue as a going concern. Future
reports from our independent registered public accounting firm may also contain statements expressing substantial doubt about our
ability to continue as a going concern. If we seek additional financing to fund our business activities in the future and there
remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling
to provide additional funding to us on commercially reasonable terms, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our new emphasis on biotherapeutic contract research and
manufacturing and COVID-19 diagnostic and surveillance testing may reduce our ability to maintain and expand our existing Non-Biologic
Tagging businesses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our new emphasis on biotherapeutic contract
research and manufacturing and COVID-19 diagnostic and surveillance testing may divert funding and our limited managerial and other
resources from our existing non-biologic tagging businesses. This may have the effect of reducing opportunities to grow or maintain
revenues in our existing businesses while at the same time we may fail in our biotherapeutic contracts research and manufacturing
and COVID-19 diagnostic and surveillance testing efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Relating to Our Product Candidates, Manufacturing,
Development, and Industries:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our Linea<SUP>TM</SUP> COVID-19 Assay Kit is being sold
under an FDA EUA.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Linea<SUP>TM</SUP> COVID-19 Assay
Kit has not been cleared or approved by FDA, but has been authorized for sale under an EUA. The FDA has the authority to
grant an EUA to allow unapproved medical products to be used in an emergency when there are no adequate, approved, and
available alternatives. The EUA authorizes our test to be used by laboratories certified to perform high complexity testing
under CLIA. The EUA includes conditions of authorization with which we must comply, including, but not limited to, compliance
with labeling, distribution of materials designed to ensure proper use, reporting obligations, and restrictions on
advertising and promotion. Distributors of and laboratories using our Linea<SUP>TM</SUP> COVID-19 Assay Kit must also comply
with the relevant provisions of our EUA. The EUA is only effective for the duration of the COVID-19 public health emergency.
The FDA may revoke or terminate the EUA sooner if, for example, we fail to comply with the terms of the EUA or our test is
determined to be less accurate than it was initially believed to be. We cannot predict how long the EUA will remain in place.
If the EUA is revoked or terminated, it could significantly harm our business, results of operations, and profits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our safeCircle<SUP>TM</SUP> surveillance testing service
could become obsolete or its utility could be significantly diminished.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Surveillance testing is not regulated by
the FDA and CMS has stated that CLIA certification is not required to conduct surveillance testing. ADCL is offering its safeCircle<SUP>TM</SUP>
surveillance testing in compliance with current CDC, FDA, CMS and New York State Department of Health recommendations. The regulatory
framework or recommendations regarding COVID-19 Surveillance Testing could change at any time. Further, our COVID-19 Surveillance
Testing may become obsolete for a variety of reasons, including an end to the current pandemic or the development and widespread
distribution of a vaccine, including the vaccines developed by Pfizer-BioNTech or Moderna for which the FDA has recently granted
emergency use authorization. In addition, the utility of these services will also diminish if positivity rates reach levels high
enough to render surveillance testing ineffective or inefficient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our Linea<SUP>TM</SUP> COVID-19 Assay Kits could become
obsolete or their utility could be significantly diminished.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Linea<SUP>TM</SUP> COVID-19 Assay Kits
may become obsolete for a variety of reasons, including an end to the current pandemic, the development and widespread distribution
of a vaccine, including the vaccines developed by Pfizer-BioNTech or Moderna for which the FDA has recently granted emergency use
authorization. In addition, future or currently undiscovered mutations to the COVID-19 virus could result in our Linea<SUP>TM</SUP>
COVID-19 Assay Kits suffering a loss of sensitivity and resulting loss of utility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our Linea<SUP>TM&nbsp;</SUP>COVID-19 Assay Kit may result
in false negatives.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">False negative test results are a risk with
all laboratory tests, including COVID-19 molecular diagnostic tests. A false negative occurs with a COVID-19 molecular diagnostic
when an individual who is infected with the virus tests negative for the virus.&nbsp; False negatives can occur in the presence
or absence of a mutation in the COVID-19 virus.&nbsp; In the presence of a mutation in the virus, false negatives can occur if
a mutation occurs in the region of the virus that the test is designed to assess.&nbsp; The risk of false negatives in the presence
of a mutation is increased with tests that only assess a single region of the COVID-19 virus as compared to tests that assess more
than one region of the virus.&nbsp; Our Linea<SUP>TM&nbsp;</SUP>COVID-19 Assay Kit test assesses two regions of the virus, thus
reducing the likelihood of false negatives in the presence of one or more COVID-19 mutations.&nbsp; Regardless, false negatives
may occur with our Linea<SUP>TM&nbsp;</SUP>COVID-19 Assay Kit in the presence or absence of one or more COVID-19 mutations.&nbsp;
If false negatives occur with our Linea<SUP>TM&nbsp;</SUP>COVID-19 Assay Kit, individuals will incorrectly believe they do not
have COVID-19 and could further spread the virus thereby jeopardizing the health of others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Other companies may develop and obtain authorization for
molecular diagnostics that can detect the 69&#8212;70del mutation. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The 69&#8212;70del mutation is a mutation
that is found in several variants of COVID-19, including, but not limited to the so called &#8220;UK Variant&#8221; or the B.1.1.7
variant.&nbsp; The B.1.1.7 variant has been associated with an increased risk of transmission.&nbsp;According to an Alert to Health
Care Providers and Clinical Laboratory Staff and a Letter to Health Care Providers and Clinical Laboratory Staff both issued by
the FDA on January 8, 2021, there are currently only two EUA authorized COVID-19 molecular diagnostics that can indicate a sample
contains the 69&#8212;70del mutation, including our Linea<SUP>TM&nbsp;</SUP>COVID-19 Assay Kit.&nbsp; Other companies may develop
and obtain Emergency Use Authorization for COVID-19 molecular diagnostics that can detect the 69&#8212;70del mutation.&nbsp; Such
tests would compete with our test and could negatively impact sales of our Linea<SUP>TM&nbsp;</SUP>COVID-19 Assay Kit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="c_001"></A>USE OF PROCEEDS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will not receive any proceeds from the
sale of the shares of common stock by the Selling Stockholders. However, we will receive proceeds from the exercise of the Warrants
by the Selling Stockholders to the extent they are exercised for cash. We estimate that the maximum proceeds that we may receive
from the exercise of the Warrants, assuming all the Warrants are exercised at their average exercise price of $7.14, will be $1,850,360.
We do not know, however, whether any of the Warrants will be exercised or, if any of the Warrants are exercised, when they will
be exercised. It is possible that the Warrants will expire and never be exercised. There are circumstances under which the Warrants
may be exercised on a cashless basis. In these circumstances, even if the Warrants are exercised, we may not receive any proceeds,
or the proceeds that we do receive may be significantly less than what we might expect. We intend to use the aggregate net proceeds
from the exercise of the Warrants for general corporate purposes, including working capital, for research and development and to
advance the adoption of our LinearDNA&#8482; manufacturing platform. The actual allocation of proceeds realized from the exercise
of these Securities will depend upon the amount and timing of such exercises, our operating revenues and cash position at such
time and our working capital requirements. The Selling Stockholders will pay any expenses incurred by the Selling Stockholders
for brokerage, accounting, tax or legal services or any other expenses incurred by the Selling Stockholders in disposing of their
shares of common stock. We will bear all other costs, fees and expenses incurred in effecting the registration of the shares covered
by this prospectus, including, without limitation, all registration fees and fees and expenses of our counsel and our accountants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="c_002"></A>DIVIDEND
POLICY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">We have never
paid cash dividends on our common stock. We anticipate that we will retain all of our future earnings, if any, for use in the expansion
and operation of our business and do not anticipate paying cash dividends in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="c_003"></A><FONT STYLE="text-transform: none">PRIVATE
PLACEMENT OF WARRANTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On July 17, 2019, we issued $1.5 million
of secured convertible notes (the &#8220;July 2019 Notes&#8221;), bearing interest at a rate of 6% per annum, in a non-brokered
private placement with an accredited investor, Dillon Hill Capital, LLC, one of the Selling Stockholders hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November 15, 2019, we closed an underwritten
public offering where we issued and sold 2,285,000 shares of our common stock and 2,285,000 accompanying common warrants (the &#8220;2019
Warrants&#8221;) each with the right to purchase one share of our common stock at an exercise price of $5.25 per share. In such
offering, the Selling Stockholders purchased certain of the 2019 Warrants. On October 7, 2020, we entered into Warrant Exercise
Agreements (each, a &#8220;Warrant Exercise Agreement&#8221;) with each of the Selling Stockholders, whereby 318,000 of our 2019
Warrants were exercised. The gross proceeds to the Company from this partial exercise of the 2019 Warrants was $1,669,500.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On October 9, 2020, the Company entered
into a letter agreement with Dillon Hill Capital, LLC as sole holder of the July 2019 Notes for the repayment in full of such notes,
in an aggregate amount of $1,665,581, representing their outstanding principal amount plus accrued but unpaid interest through
their scheduled maturity date. The Company paid such payoff amount on October 9, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In consideration of this partial exercise
of the 2019 Warrants and of the consent to repayment of the July 2019 Notes, the Company agreed to issue pursuant to the Warrant
Exercise Agreement (the &#8220;Private Placement&#8221;), in addition to the 318,000 shares of common stock issued upon exercise of
the 2019 Warrants, 159,000 replacement warrants (the &#8220;Warrants&#8221;) to the Selling Stockholders, which is an amount equal
to one-half the amount of the 2019 Warrants exercised pursuant to the Warrant Exercise Agreements. The Warrants have an average
exercise price of $7.54, the closing price on The Nasdaq Capital Market of the Company&#8217;s common stock on the date of the
applicable warrant exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The quantity, issue date, exercise price
and expiration date of the Warrants are listed in the table below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt; font-weight: bold">Quantity</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Issuance Date</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Exercise Price</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Expiration Date</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 23%; font-size: 10pt; text-align: right">159,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 25%; font-size: 10pt; padding-bottom: 1pt; text-indent: 0in; padding-left: 5.4pt">October 7, 2020</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 22%; font-size: 10pt; text-align: right">7.54</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 24%; font-size: 10pt; padding-bottom: 1pt; text-indent: 0in; padding-left: 5.4pt">October 7, 2025</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: right">50,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-indent: 0in; padding-left: 5.4pt">December 9, 2020</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">6.57</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-indent: 0in; padding-left: 5.4pt">December 9, 2025</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: right">50,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-indent: 0in; padding-left: 5.4pt">December 10, 2020</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">6.46</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-indent: 0in; padding-left: 5.4pt">December 10, 2025</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each Warrant is exercisable for one share
of common stock beginning on the date of issuance thereof and ending on the five year anniversary of such date. The exercise price
and number of shares of common stock issuable upon exercise of the Warrants are subject to adjustment in the event of any stock
dividend, split, recapitalization, reorganization or similar transaction, as described in the Warrants. Subject to limited exceptions,
a holder of a Warrant will not have the right to exercise any portion of its Warrant if the holder, together with its affiliates,
would beneficially own in excess of 9.99% of the number of shares of common stock outstanding immediately after giving effect to
such exercise (the &#8220;Beneficial Ownership Limitation&#8221;); provided that upon 61 days&#8217; prior notice to the Company,
the holder may elect to increase or decrease the Beneficial Ownership Limitation, although in no event may the Beneficial Ownership
Limitation exceed 9.99%. Each Warrant includes an adjustment provision that, subject to certain exceptions, reduces its exercise
price if the Company issues common stock or common stock equivalents at a price lower than the then-current exercise price of such
Warrant, subject to a minimum exercise price of 21% of such Warrant&#8217;s initial exercise price per share. Under certain limited
circumstances, including that the daily volume weighted average price of the common stock for each of 20 consecutive trading days
has exceeded three times the exercise price of such Warrant, the Company may call for cancellation of all or any portion of such
Warrant for which a notice of exercise has not yet been delivered for consideration equal to $0.001 per share of common stock for
which such Warrant is excisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Warrants will not be registered nor
listed on any exchange but are the subject of registration rights agreements, entered into with each Selling Stockholder concurrently
with the respective Warrant Exercise Agreement, pursuant to which the Company agreed to file a registration statement by January
20, 2021 with respect to the common stock underlying the Warrants. If at the time of exercise of the Warrants there is no effective
registration statement registering, or the prospectus contained therein is not available for the issuance of the common stock underlying
the Warrants to the applicable Selling Stockholder, then such Warrant may also be exercised, in whole or in part, at such time
by means of a &#8220;cashless exercise&#8221; in which the Selling Stockholder will be entitled to receive a number of shares of
common stock as determined by the terms of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Private Placement is further described
in the Company&#8217;s Periodic Report on Form 8-K filed October 14, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The private placement of the Warrants was
completed in reliance upon the exemption from registration provided for by Section 4(a)(2) of the Securities Act or 1933 as amended
(the &#8220;Securities Act&#8221;) and by Rule 506 of Regulation D promulgated under the Securities Act. Each Selling Stockholder
represented to the Company in its Warrant Exercise Agreement that it is an &#8220;accredited investor&#8221; as that term is defined
in Rule 501 of Regulation D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="c_004"></A><FONT STYLE="text-transform: none">SELLING
STOCKHOLDERS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have prepared this prospectus to allow
the Selling Stockholders we have identified herein, including their transferees, pledgees, donees and successors in interest, to
offer for resale up to 259,000 shares of our common stock (assuming exercise of all Warrants).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The common stock being offered by the Selling
Stockholders is that issuable to the Selling Stockholders upon exercise of the Warrants. For additional information regarding the
issuances of those shares of common stock and Warrants, see &#8220;Private Placement of Warrants&#8221; above. We are registering
the shares of common stock in order to permit the Selling Stockholders to offer the Securities for resale from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The registration of the sale of shares of
common stock held by the Selling Stockholders does not mean that they will sell or otherwise dispose of all or any of those securities.
The Selling Stockholders may sell or otherwise dispose of all, a portion or none of such shares from time to time. See &#8220;Plan
of Distribution.&#8221; We do not know the number of shares, if any, that will be offered for sale or other disposition by any
of the Selling Stockholders under this prospectus. Furthermore, the Selling Stockholders may have sold, transferred or disposed
of the shares of common stock covered hereby in transactions exempt from the registration requirements of the Securities Act since
the date on which we filed this prospectus. As a result, we cannot estimate the number of shares of common stock each of the Selling
Stockholders will beneficially own after termination of sales under this prospectus. In addition, each of the Selling Stockholders
may have sold, transferred or otherwise disposed of all or a portion of its shares of common stock since the date on which it provided
information for the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with the terms of a registration
rights agreement with the Selling Stockholders, this prospectus generally covers the resale of the maximum number of shares of
common stock issuable upon exercise of the Warrants issued pursuant to the Warrant Exercise Agreements, determined as if the outstanding
Warrants were exercised in full as of the trading day immediately preceding the date this registration statement was initially
filed with the SEC, without regard to any limitations on the exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Except as otherwise described in this prospectus,
none of the Selling Stockholders has, or within the past three years has had, any position, office or other material relationship
with us or any of our affiliates. None of the Selling Stockholders is a broker-dealer or an affiliate of a broker-dealer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The table below sets forth certain information
with respect to each Selling Stockholder, including (i) the name of each Selling Stockholder; (ii) the number of shares of our
common stock beneficially owned by each Selling Stockholder before this offering; (iii) the maximum number of shares being offered
by each Selling Stockholder pursuant to this prospectus; and (iv) each Selling Stockholder&#8217;s beneficial ownership after completion
of this offering, assuming that all of the shares covered hereby (but no other shares, if any, held by the Selling Stockholders)
are sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The table is based on information supplied
to us by the Selling Stockholders or in Schedules 13G or 13D and other public documents filed with the SEC, with beneficial ownership
and percentage ownership determined in accordance with the rules and regulations of the SEC, and includes information with respect
to voting or investment power with respect to shares of stock. This information does not necessarily indicate beneficial ownership
for any other purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The percentage of each Selling Stockholder&#8217;s
ownership before and after this offering is based on 7,471,474 shares of common stock outstanding as of January 15, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 20%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Name and Address<BR>
of Selling<BR>
Stockholders</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 19%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No. of Shares of<BR>
Common Stock <BR>
Beneficially <BR>
Owned Prior to <BR>
this Offering</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 19%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Percentage of<BR>
Outstanding<BR>
Shares of<BR>
Common Stock<BR>
Beneficially<BR>
Owned Prior to<BR>
this Offering<SUP>1</SUP></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 19%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No. of Shares of <BR>
Common Stock <BR>
Offered by <BR>
Selling<BR>
Stockholders</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 19%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No. and<BR>
Percentage of<BR>
Outstanding<BR>
Shares of<BR>
Common Stock<BR>
Beneficially<BR>
Owned<BR>
Subsequent to this <BR>
Offering<SUP>2</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><B>Dillon Hill Capital, LLC<SUP>3</SUP></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">301,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3.9%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">100,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">201,000 ; 2.6%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Dillon Hill Investment Company LLC<SUP>3</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">357,739</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">4.6%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">159,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">198,739 ; 2.6%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><SUP>1 </SUP>Includes
the common stock issued upon the exercise of the 2019 Warrants under the applicable Warrant Exercise Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><SUP>2 </SUP>We have
assumed that the Selling Stockholders will not acquire beneficial ownership of any additional securities issued by us during the
Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;Assumes all Warrants are exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><SUP>3</SUP> Based
on a Schedule 13G/A filed with the SEC on January 20, 2021, Bruce Grossman is the sole member of Dillon Hill Capital, LLC and
a trust of which Bruce Grossman&#8217;s spouse is the co-trustee is the sole member of Dillon Hill Investment Company LLC. As
such, Bruce Grossman may be deemed to beneficially own the securities held of record by the Selling Stockholders. Bruce
Grossman disclaims any such beneficial ownership. The principal business address of Bruce Grossman is c/o Dillon Hill Capital
LLC, 200 Business Park Drive, Suite 306, Armonk, NY 10504. <FONT STYLE="background-color: white">If required, information
about other selling stockholders, except for any future transferees, pledgees, donees or successors of the </FONT>Selling
Stockholders <FONT STYLE="background-color: white">named in the table above, will be set forth in a prospectus supplement or
amendment to the registration statement of which this prospectus is a part. Additionally, post-effective amendments to the
registration statement will be filed to disclose any material changes to the plan of distribution from the description
contained in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="c_005"></A>PLAN OF
DISTRIBUTION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are registering the shares of common
stock issuable to the Selling Stockholders upon the exercise of the Selling Stockholders&#8217; Warrants purchased in the Private
Placement to permit the resale of these shares of common stock by the holders of the shares of common stock from time to time after
the date of this prospectus. We will not receive any of the proceeds from the sale by the Selling Stockholders of the shares of
common stock. We will bear all fees and expenses incident to our obligation to register the shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Selling Stockholders, which may include
donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests in shares of common stock
received after the date of this prospectus from a Selling Stockholder as a gift, pledge, partnership distribution or other transfer,
may sell all or a portion of the shares of common stock beneficially owned by them and offered hereby from time to time on any
stock exchange, market or trading facility on which the shares are traded or in private transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A Selling Stockholder may use any one or
more of the following methods when disposing of shares or interests therein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&#8226;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&#8226;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&#8226;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its own account; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&#8226;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">an exchange distribution in accordance with the rules of the applicable exchange; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&#8226;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">privately negotiated transactions; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&#8226;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&#8226;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">through agreements between broker-dealers and the Selling Stockholders to sell a specified number of such shares at a stipulated price per share; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&#8226;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">a combination of any such methods of sale; and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&#8226;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">any other method permitted by applicable law. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Selling Stockholders may, from time
to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in
the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from
time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b) or other applicable provision of
the Securities Act amending the list of selling stockholders to include the pledgee, transferee or other successors in interest
as selling stockholders under this prospectus. The Selling Stockholders also may transfer the shares of common stock in other circumstances,
in which case the pledgees, transferees or other successors in interest will be the selling beneficial owners for purposes of this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Selling Stockholders also may resell
all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act, as permitted by
that rule, or Section 4(a)(1) under the Securities Act, if available, rather than under this prospectus; provided that they meet
the criteria and conform to the requirements of those provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the sale of our
common stock or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other
financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions
they assume. The Selling Stockholders may also sell shares of our common stock short and deliver these securities to close
out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The
Selling Stockholders may also enter into options or other transactions with broker-dealers or other financial institutions or
the creation of one or more derivative securities which require the delivery to each such broker-dealer or other financial
institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell
pursuant to this prospectus (as supplemented or amended to reflect such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;The aggregate proceeds to the Selling
Stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or
commissions, if any. Each of the Selling Stockholders reserves the right to accept and, together with its agents from time to time,
to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive
any of the proceeds from this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Selling Stockholders and any underwriters,
broker-dealers or agents that participate in the sale of the common stock or interests therein may be &#8220;underwriters&#8221;
within the meaning of Section&nbsp;2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on
any resale of the shares may be underwriting discounts and commissions under the Securities Act. Selling Stockholders who are &#8220;underwriters&#8221;
within the meaning of Section&nbsp;2(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To the extent required, the shares of our
common stock to be sold, the names of the selling stockholders, the respective purchase prices and public offering prices, the
names of any agents, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will
be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement
that includes this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If underwriters are used in the sale, the
shares of common stock will be acquired by the underwriters for their own account and may be resold from time to time in one or
more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time
of sale. In connection with any such underwritten sale of shares of common stock, underwriters may receive compensation from the
selling stockholders, for whom they may act as agents, in the form of discounts, concessions or commissions. If the selling stockholders
use an underwriter or underwriters to effectuate the sale of shares of common stock, we and/or they will execute an underwriting
agreement with those underwriters at the time of sale of those shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To the extent required by law, the names
of the underwriters will be set forth in a prospectus supplement or, if appropriate, a post-effective amendment to the registration
statement that includes the prospectus supplement and the accompanying prospectus used by the underwriters to sell those securities.
The obligations of the underwriters to purchase those shares of common stock will be subject to certain conditions precedent, and
unless otherwise specified in a prospectus supplement, the underwriters will be obligated to purchase all the shares of common
stock offered by such prospectus supplement if any of such shares of common stock are purchased. Any public offering price and
any discounts or concessions allowed or re-allowed or paid to dealers may be changed from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have advised the Selling Stockholders
that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities
of the Selling Stockholders and their affiliates. The Selling Stockholders may indemnify any broker-dealer that participates in
transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are required to pay certain fees and
expenses incurred by us incident to the registration of the shares of common stock of the selling stockholders. We have agreed
to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the
Securities Act, and the Selling Stockholders may be entitled to contribution. We may be indemnified by the Selling Stockholders
against certain losses, claims, damages and liabilities, including liabilities under the Securities Act that may arise from any
written information furnished to us by the Selling Stockholders specifically for use in this prospectus, or we may be entitled
to contribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have agreed with the Selling Stockholders
to keep the registration statement of which this prospectus forms a part effective until the earlier of (i)&nbsp;the date as of
which the Selling Stockholders may sell all of the common stock covered by such registration statement without restriction or limitation pursuant to Rule 144 and without the requirement to be
in compliance with Rule 144(c)(1) (or any successor thereto) promulgated under the Securities Act or (ii) the date on which the Selling
Stockholders shall have sold all of the common stock covered by such registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our common stock is listed on The Nasdaq Capital Market under the symbol &ldquo;APDN.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_008"></A>LEGAL MATTERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The validity of the issuance of the Securities
offered hereby will be passed upon for us by Troutman Pepper Hamilton Sanders LLP, New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_009"></A>EXPERTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Marcum LLP, independent registered public
accounting firm, has audited our consolidated financial statements included in our <A HREF="http://www.sec.gov/Archives/edgar/data/744452/000110465920136828/tm2037742d1_10k.htm" STYLE="-sec-extract: exhibit">Annual
Report on Form 10-K for the year ended September 30, 2020 (as amended)</A>, as set forth in their report, which includes an explanatory
paragraph as to the Company&#8217;s ability to continue as a going concern as described in Note B to the consolidated financial
statements, dated December 17, 2020, which is incorporated by reference in the prospectus and elsewhere in this registration statement.
Our consolidated financial statements are incorporated by reference in reliance on Marcum LLP&#8217;s report, given on their authority
as experts in accounting and auditing. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_010"></A>WHERE YOU
CAN FIND MORE INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have filed with the SEC a registration
statement on Form S-3 (File No. 333-252280), of which this prospectus is a part, under the Securities Act, to register the shares
of common stock offered by this prospectus. However, this prospectus does not contain all of the information contained in the
Registration Statement. We have omitted from this prospectus some parts of the Registration Statement as permitted by the rules
and regulations of the SEC. Statements in this prospectus concerning any document we have filed as an exhibit to the Registration
Statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified in their entirety by
reference to these filings. In addition, we file annual, quarterly and other reports, proxy statements and other information with
the SEC. Our SEC filings are available to the public over the Internet at the SEC&rsquo;s website at www.sec.gov. Our Annual Report
on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, including any amendments to those reports, and
other information that we file with or furnish to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act can also be accessed
free of charge through the Internet. These filings will be available as soon as reasonably practicable after we electronically
file such material with, or furnish it to, the SEC. Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K, including any amendments to those reports, and other information that we file with or furnish to the SEC pursuant
to Section 13(a) or 15(d) of the Exchange Act, can also be accessed free of charge from our website at http://www.adnas.com. These
filings will be available as soon as reasonably practicable after we electronically file such material with, or furnish it to,
the SEC. Information contained on our website is not part of this prospectus. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_011"></A>&nbsp;INFORMATION
INCORPORATED BY REFERENCE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have elected to incorporate certain information
by reference into this prospectus. By incorporating by reference, we can disclose important information to you by referring you
to other documents we have filed or will file with the SEC. The information incorporated by reference is deemed to be part of this
prospectus, except for information incorporated by reference that is superseded by information contained in this prospectus.
This means that you must look at all of the SEC filings that we incorporate by reference to determine if any statements in the
prospectus or any document previously incorporated by reference have been modified or superseded. This prospectus incorporates
by reference the documents set forth below that we have previously filed with the SEC, except in each case the information contained
in such document to the extent &#8220;furnished&#8221; and not &#8220;filed&#8221;:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt"> <FONT STYLE="font-family: Symbol">&middot;</FONT> </TD><TD> <A HREF="http://www.sec.gov/Archives/edgar/data/744452/000110465920136828/tm2037742d1_10k.htm" STYLE="-sec-extract: exhibit">Our
                                         Annual Report on Form 10-K for the year ended September 30, 2020, as filed with the SEC
                                         on December 17, 2020, as amended by Amendment No. 1 filed on January 27, 2021</A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 76px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/744452/000110465920113418/tm2032734d1_8k.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Current Report on Form 8-K, as filed with the SEC on October 8, 2020</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_8k.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Current Report on Form 8-K, as filed with the SEC on October 14, 2020</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/744452/000110465920116419/tm2033883-1_8k.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Current Report on Form 8-K, as filed with the SEC on October 20, 2020</FONT> </A></TD></TR>

<TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><A HREF="http://www.sec.gov/Archives/edgar/data/744452/000110465921002738/tm212720d1_8k.htm" STYLE="-sec-extract: exhibit">Our Current Report on Form 8-K, as filed with the SEC on January 11, 2021</A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><A HREF="http://www.sec.gov/Archives/edgar/data/744452/000110465921003781/tm212922-2_8k.htm" STYLE="-sec-extract: exhibit">Our Current Report on Form 8-K, as filed with the SEC on January 13, 2021</A></TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><P STYLE="margin: 0pt 0; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/744452/000110465921003781/tm212922-2_8k.htm" STYLE="-sec-extract: exhibit">Our Current Report on Form 8-K, as filed with the SEC on January 20, 2021</A></P></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><A HREF="http://www.sec.gov/Archives/edgar/data/744452/000157104914006275/t1402186_8a12b.htm" STYLE="-sec-extract: exhibit">The description of our capital stock contained in our registration statement on Form 8-A (File No. 001-36745) filed with the Commission on November 13, 2014, pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All reports and other documents subsequently
filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of the registration statement to
which this prospectus forms a part of and prior to the effectiveness of such registration statement or after the date of this prospectus
and prior to the termination or completion of the offering of Securities under this prospectus shall be deemed to be incorporated
by reference in this prospectus and to be a part hereof from the date of filing such reports and other documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You may obtain a copy of any or all of the
documents referred to above which may have been or may be incorporated by reference into this prospectus, except for exhibits to
those documents (unless the exhibits are specifically incorporated by reference into those documents) at no cost to you by writing
or telephoning us at the following address: Office of the Corporate Secretary, Applied DNA Sciences, Inc., 50 Health Sciences Drive,
Stony Brook, New York 11790, telephone (631) 240-8800.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.85pt">Annual Reports on Form 10-K, Quarterly
Reports on Form 10-Q and Current Reports on Form 8-K, including any amendments to those reports, and other information that we
file with or furnish to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act, can also be accessed free of charge from
our website at http://www.adnas.com. These filings will be available as soon as reasonably practicable after we electronically
file such material with, or furnish it to, the SEC. Information contained on our website is not part of this prospectus.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.85pt"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 47.85pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid; padding: 0.5pt 1.25pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm214491d1_s3img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>259,000 Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Offered by the Selling Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 21%; padding: 0.25pt 1.25pt">&nbsp;</TD>
    <TD STYLE="width: 57%; border-top: black 1pt solid; padding: 0.5pt 1.25pt 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 22%; padding: 0.25pt 1.25pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt 1.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.75pt 1.25pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>PROSPECTUS</B></FONT></TD>
    <TD STYLE="padding: 0.25pt 1.25pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt 1.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 0.25pt 1.25pt 0.5pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 1.25pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>January &nbsp;&nbsp;&nbsp;, 2021</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 1%; padding: 1pt">&nbsp;</TD>
    <TD STYLE="width: 98%; padding: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding: 1pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid; padding: 0.5pt 1.25pt">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_012"></A>INFORMATION
NOT REQUIRED IN THE PROSPECTUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 13. Disclosure of Commission Position on Indemnification
for Securities Act Liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Insofar as indemnification for liabilities
arising under the Securities Act of 1933 may be permitted to directors, officers or persons controlling the registrant pursuant
to the foregoing provisions, the registrant has been informed that in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Act and is therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 14. Other Expenses of Issuance and Distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Set forth below is an estimate (except in
the case of the registration fee) of the amount of fees and expenses to be incurred in connection with the issuance and distribution
of the offered Securities registered hereby, other than underwriting discounts and commissions, if any, incurred in connection
with the sale of the offered Securities. All such amounts will be borne by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: justify"><FONT STYLE="font-size: 10pt">SEC Registration Fee</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right">257</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Legal Fees and Expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">30,000</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Accounting Fees and Expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">7,500</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt">Miscellaneous Fees and Expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt">Total:</FONT></TD>
    <TD STYLE="padding-top: 1pt">&nbsp;</TD>
    <TD STYLE="padding-top: 1pt"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="padding-top: 1pt; text-align: right">39,757</TD>
    <TD STYLE="padding-top: 1pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 15. Indemnification of Directors and Officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_013"></A>INDEMNIFICATION
FOR SECURITIES ACT LIABILITIES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Certificate of Incorporation provides
to the fullest extent permitted by Delaware law that our directors or officers shall not be personally liable to us or our stockholders
for damages for breach of such director&#8217;s or officer&#8217;s fiduciary duty. The effect of this provision of our Certificate
of Incorporation is to eliminate our rights and the rights of our stockholders (through stockholders&#8217; derivative suits on
behalf of our company) to recover damages against a director or officer for breach of the fiduciary duty of care as a director
or officer (including breaches resulting from negligent or grossly negligent behavior), except under certain situations defined
by statute. We believe that the indemnification provisions in our Certificate of Incorporation are necessary to attract and retain
qualified persons as directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Certificate of Incorporation also provides
that we shall have the power to indemnify, to the extent permitted by the Delaware General Corporation Law, as it presently exists
or may hereafter be amended from time to time, any employee or agent of ours who was or is a party or is threatened to be made
a party to any proceeding by reason of the fact that he or she is or was a director, officer, employee or agent of ours or is or
was serving at our request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust
or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys&#8217; fees),
judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any such proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.3 of our By-Laws provides for
the indemnification of our directors, officers and employees to the fullest extent permitted by the Delaware General Corporation
Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have entered into an
indemnification agreement (each, an &#8220;Indemnification Agreement&#8221;) with each of our directors and executive
officers. In general, the Indemnification Agreement obligates us to indemnify a director or executive officer, to the fullest
extent permitted by applicable law, for certain expenses, including attorneys&#8217; fees, judgments, penalties, fines and
settlement amounts actually and reasonably incurred by them in any action or proceeding arising out of their services as one
of our directors or executive officers, or any of our subsidiaries or any other company or enterprise to which the person
provides services at our request. In addition, the Indemnification Agreement provides for the advancement of expenses
incurred by the indemnitee in connection with any covered proceeding to the fullest extent permitted by applicable law. The
rights provided by the Indemnification Agreement are in addition to any other rights to indemnification or advancement of
expenses to which the indemnitee may be entitled under applicable law, our Certificate of Incorporation, as amended, or
bylaws, or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Insofar as indemnification for liabilities
arising under the Securities Act of 1933, as amended, may be permitted to directors, officers and controlling persons of ours pursuant
to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by us of expenses incurred or paid by a director, officer or controlling person
of ours in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person
in connection with the Securities being registered, we will, unless in the opinion of our counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against
public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We maintain a director and officer insurance
policy that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their
capacities as directors or officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Item 16. Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A list of exhibits
filed with this registration statement on Form S-3 is set forth on the Exhibit Index and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 17. Undertakings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned
Registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to file, during
any period in which offers or sales are being made, a post-effective amendment to this registration statement: (i) to include any
prospectus required by Section 10(a)(3) of the Securities Act; (ii) to reflect in the prospectus any facts or events arising after
the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in
the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing,
any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that
which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the
form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent
no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221;
table in the effective registration statement; and (iii) to include any material information with respect to the plan of distribution
not previously disclosed in the registration statement or any material change to such information in the registration statement;
provided, however, that paragraphs (i), (ii) and (iii) do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section
13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement, or is contained in a
form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that, for the
purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to remove from
registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
of the offering; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(4) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that, for the
purpose of determining liability under the Securities Act to any purchaser: (i) Each prospectus filed by the Registrant pursuant
to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part
of and included in the registration statement; and (ii) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5)
or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i),
(vii) or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be
part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness
or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B,
for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new
effective date of the registration statement relating to the securities in the registration statement to which the prospectus relates,
and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however,
that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document
incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration
statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement
that was made in the registration statement or prospectus that was part of the registration statement or made in any such document
immediately prior to such effective date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned
Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of Registrant&#8217;s
annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in this registration
statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insofar as
indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling
persons of the registrant pursuant to the provisions described under Item 15 above, or otherwise, the Registrant has been
advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as
expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such
liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling
person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer
or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its
counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question
whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the
final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Pursuant to the requirements of the
Securities Act of 1933, as amended, the registrant, Applied DNA Sciences, Inc., certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its
behalf by the undersigned, thereunto duly authorized, in Stony Brook, State of New York, on the 28th day of January 2021. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">APPLIED DNA SCIENCES, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT>&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 47%"><FONT STYLE="font-size: 10pt">/s/ James A. Hayward </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">James A. Hayward</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Chairman, President and Chief Executive Officer</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Options: NewSection; Value: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Act of 1933 this
registration statement has been signed by the following persons in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 32%; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Signature</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%; text-align: center"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 33%; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Title</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%; text-align: center"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 32%; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Date</B></FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"> <FONT STYLE="font-size: 10pt">/s/ JAMES A. HAYWARD</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">Chairman, President, Chief</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">January 28, 2021</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">James A. Hayward</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">Executive Officer and Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt; color: #333333"><I>(Principal Executive Officer</I>)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"> <FONT STYLE="font-size: 10pt">/s/ BETH M. JANTZEN</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">January 28, 2021</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">Beth M. Jantzen</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt; color: #333333"><I>(Principal Financial Officer and Principal Accounting Officer</I>)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"> <FONT STYLE="font-size: 10pt">/s/ JOHN BITZER, III*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">January 28, 2021</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">John Bitzer, III</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"> <FONT STYLE="font-size: 10pt">/s/ ROBERT CATELL*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">January 28, 2021</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">Robert Catell</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"> <FONT STYLE="font-size: 10pt">/s/ JOSEPH D. CECCOLI*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">January 28, 2021</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">Joseph D. Ceccoli</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"> <FONT STYLE="font-size: 10pt">/s/ SCOTT L. ANCHIN*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">January 28, 2021</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">Scott L. Anchin</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"> <FONT STYLE="font-size: 10pt">/s/ YACOVA A. SHAMASH*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">January 28, 2021</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">Yacova A. Shamash</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"> <FONT STYLE="font-size: 10pt">/s/ SANFORD R. SIMON*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">January 28, 2021</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">Sanford R. Simon</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"> <FONT STYLE="font-size: 10pt">/s/ ELIZABETH M. SCHMALZ FERGUSON*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">January 28, 2021</FONT> </TD></TR>
<TR>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-size: 10pt">Elizabeth M. Schmalz Ferguson</FONT> </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 3%"> *By&nbsp;&nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%"> /s/ Beth M. Jantzen &nbsp; </TD>
    <TD STYLE="width: 50%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> Beth M. Jantzen, Attorney-in-fact </TD>
    <TD> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="a_014"></A>EXHIBIT
INDEX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 9%"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="padding: 0.25pt 0.25pt 1pt; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 90%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/744452/000110465920113065/tm2032414d1_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">3.1</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/744452/000110465920113065/tm2032414d1_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Conformed version of Certificate of Incorporation of the Registrant, as most recently amended by the Fifth Certificate of Amendment, effective Thursday, September 17, 2020 filed as an exhibit to the Form S-8 filed with the Commission on October 7, 2020 and incorporated herein by reference.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/744452/000118811209000105/ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">3.2</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/744452/000118811209000105/ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">By-Laws of the Registrant filed as an exhibit to the current report on Form 8-K filed with the Commission on January 16, 2009 and incorporated herein by reference.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.1</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Warrant Exercise Agreement, dated October 7, 2020, by and between the Registrant and Dillon Hill Capital, LLC filed as an exhibit to the current report on Form 8-K filed with the Commission on October 14, 2020 and incorporated herein by reference.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.2</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Warrant Exercise Agreement, dated October 7, 2020, by and between the Registrant and Dillon Hill Investment Company LLC filed as an exhibit to the current report on Form 8-K filed with the Commission on October 14, 2020 and incorporated herein by reference.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.3</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form of Common Stock Purchase Warrant issued by the Registrant filed as an exhibit to the current report on Form 8-K filed with the Commission on October 14, 2020 and incorporated herein by reference.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-4.htm"><FONT STYLE="font-size: 10pt">4.4</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-4.htm"><FONT STYLE="font-size: 10pt">Registration Rights Agreement, dated October 7, 2020, by and between the Registrant and Dillon Hill Capital, LLC filed as an exhibit to the current report on Form 8-K filed with the Commission on October 14, 2020 and incorporated herein by reference.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">4.5</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_ex10-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Registration Rights Agreement, dated October 7, 2020, by and between the Registrant and Dillon Hill Investment Company, LLC filed as an exhibit to the current report on Form 8-K filed with the Commission on October 14, 2020 and incorporated herein by reference.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/744452/000110465921006011/tm213670d1_ex5-1.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">5.1</FONT> </A></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/744452/000110465921006011/tm213670d1_ex5-1.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">Opinion
    of Troutman Pepper Hamilton Sanders LLP (previously filed)</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; text-align: center"><A HREF="tm214491d1_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">23.1</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: left"><A HREF="tm214491d1_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Consent of Marcum LLP</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/744452/000110465921006011/tm213670d1_ex5-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">23.2</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/744452/000110465921006011/tm213670d1_ex5-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Consent of Troutman Pepper Hamilton Sanders LLP (included in Exhibit 5.1)</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 34; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>tm214491d1_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the incorporation by reference
in this Registration Statement of Applied DNA Sciences, Inc. on Amendment No. 1 to Form S-3 [File No. 333-252280] of our report
dated December 17, 2020, which includes an explanatory paragraph as to the Company&rsquo;s ability to continue as a going concern,
with respect to our audits of the consolidated financial statements of Applied DNA Sciences, Inc. as of September 30, 2020 and
2019 and for each of the two years in the period ended September 30, 2020 appearing in the Annual Report on Form 10-K of Applied
DNA Sciences, Inc. for the year ended September 30, 2020. We also consent to the reference to our firm under the heading &ldquo;Experts&rdquo;
in the Prospectus, which is part of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Marcum <FONT>LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marcum <FONT>LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Melville, NY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">January 28, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm214491d1_s3img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm214491d1_s3img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  W 5<# 2(  A$! Q$!_\0
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MCE!D<OC]XX<$GR\  _5C]C+]O#X5_M^_"<>,_A5XNLO%.C))Y%R(T>&ZT^7
M;RIX7"R1M@Y&Y<$<J2.:\#_;@_X.#?V9/V!_BA-X+\7^,;[5?%=DP6_TSP_I
MSZA)I9(SMG<%8T?_ &-^\=U%?G=_P3F/AK]E;_@X0_:O\/\ P#>#_A4ND> K
M_4KJRL)O-TVTO8(K*4HAR5Q#>R7,2#^ -(B\ UL_\&FOP"^"W[2_P*^*GCGQ
MUHWA?XA_&>_\57 UE_$-I#J5W;V,L,4B2K',K;5FF>Y+R#ERFTGY<4 ?K/\
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B\VTX!*APN>U%% 'T((PO:G444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
